FDA
-
-
-
-
-
-
-
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Societ
-
-
-
-
-
-
-
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
-
-
-
-
-
-
-
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
-
-
-
-
-
-
-
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment
-
-
-
-
-
-
-
Catabasis Pharma (CATB) Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in DMD
-
-
-
-
-
-
-
Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
-
253,536 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All